{"id":"W2034826891","doi":"10.1007/s00280-013-2078-0","title":"An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":25,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Heart, Lung, and Blood Institute; Georgia Cancer Coalition; Health Canada; National Institute on Aging; Aflac; U.S. Food and Drug Administration; National Cancer Institute; National Institutes of Health","keywords":"Bortezomib; In vivo; Protein kinase B; PI3K/AKT/mTOR pathway; Angiogenesis; Proteasome inhibitor; Phosphoinositide 3-kinase; Cancer research; Medicine; Pharmacology; Multiple myeloma; Biology; Immunology; Signal transduction; Cell biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002101033,0.0005554121,0.0006870273,0.0003675648,0.000250956,0.0003565056,0.0002511892,0.0003608629,0.001439251],"category_scores_gemma":[0.0001208884,0.0001933709,0.0003325589,0.0003632168,0.0002135279,0.0002251734,0.00008818326,0.00110555,0.0003968008],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003643279,"about_ca_system_score_gemma":0.0004142818,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001477396,"about_ca_topic_score_gemma":0.002635889,"domain_scores_codex":[0.999863,0.00001641931,0.0000126678,0.00002072848,0.00003842728,0.00004882404],"domain_scores_gemma":[0.9999171,0.00001258854,0.0000220836,0.00001152087,0.00000767274,0.00002908387],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001804374,0.0003235847,0.0003855815,0.00008335765,0.00003383303,0.00006520181,0.00001732135,0.0003283968,0.9883432,0.0001193598,0.0004592535,0.008036532],"study_design_scores_gemma":[0.0002347717,0.002221886,0.002948092,0.000004148477,0.00005110713,0.0003439341,0.00001076495,0.0008471529,0.9907803,0.00003983721,0.002512212,0.000005698545],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9881665,0.005003158,0.001636078,0.0004286761,0.0001276389,0.00004124408,0.0008345088,0.0003504089,0.003411639],"genre_scores_gemma":[0.9919291,0.002287586,0.001468674,0.00008246327,0.00003079077,0.00003133901,0.001438534,0.00002750791,0.002704129],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001477396,"threshold_uncertainty_score":0.004814744,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01321246466228843,"score_gpt":0.2847992486588463,"score_spread":0.2715867839965579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}